164 related articles for article (PubMed ID: 22164556)
21. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
[TBL] [Abstract][Full Text] [Related]
22. Influenza infection and vaccination in pregnant women.
Tamma PD; Steinhoff MC; Omer SB
Expert Rev Respir Med; 2010 Jun; 4(3):321-8. PubMed ID: 20524915
[TBL] [Abstract][Full Text] [Related]
23. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women.
Dodds L; McNeil SA; Fell DB; Allen VM; Coombs A; Scott J; MacDonald N
CMAJ; 2007 Feb; 176(4):463-8. PubMed ID: 17296958
[TBL] [Abstract][Full Text] [Related]
24. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
Nichol KL
Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the impact of immunization policies, including the addition of pharmacists as immunizers, on influenza vaccination coverage in Nova Scotia, Canada: 2006 to 2016.
Isenor JE; O'Reilly BA; Bowles SK
BMC Public Health; 2018 Jun; 18(1):787. PubMed ID: 29940903
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
[TBL] [Abstract][Full Text] [Related]
28. Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.
Dawa J; Emukule GO; Barasa E; Widdowson MA; Anzala O; van Leeuwen E; Baguelin M; Chaves SS; Eggo RM
BMC Med; 2020 Aug; 18(1):223. PubMed ID: 32814581
[TBL] [Abstract][Full Text] [Related]
29. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
Allsup S; Gosney M; Haycox A; Regan M
Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
[TBL] [Abstract][Full Text] [Related]
30. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
31. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
de Boer PT; Backer JA; van Hoek AJ; Wallinga J
BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
[TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C
Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
34. Program cost analysis of influenza vaccination of health care workers in Albania.
Pallas SW; Ahmeti A; Morgan W; Preza I; Nelaj E; Ebama M; Levin A; Lafond KE; Bino S
Vaccine; 2020 Jan; 38(2):220-227. PubMed ID: 31669063
[TBL] [Abstract][Full Text] [Related]
35. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
[TBL] [Abstract][Full Text] [Related]
37. Influenza vaccination during pregnancy and influencing factors in Korea: A multicenter questionnaire study of pregnant women and obstetrics and gynecology doctors.
Kang BS; Lee SH; Kim WJ; Wie JH; Park IY; Ko HS
BMC Pregnancy Childbirth; 2021 Jul; 21(1):511. PubMed ID: 34271867
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial.
Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
Vaccine; 2013 Apr; 31(17):2156-64. PubMed ID: 23499607
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
Van Bellinghen LA; Marijam A; Tannus Branco de Araujo G; Gomez J; Van Vlaenderen I
Braz J Infect Dis; 2018; 22(1):1-10. PubMed ID: 29352897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
